Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial.
Depression is common in multiple sclerosis (MS) patients, but tricyclic compounds are not well tolerated and newer antidepressants have not been studied. Effects of 150-400 mg/day of moclobemide, a reversible monoamine oxidase A inhibitor, were studied in a 3-month open design in 10 MS patient with DSM-IV-diagnosed depression. Nine patients reached complete remission. No adverse effects were noted. Four patients reported side effects including nausea and insomnia. The authors conclude that moclobemide is a well tolerated and efficient treatment for depression comorbid with MS.
Barak
Y
Y
Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel.
Ur
E
E
Achiron
A
A
D000328:Adult; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide / Q000009:adverse effects / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000150:complications*; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales
D020912:Moclobemide